高级检索
当前位置: 首页 > 详情页

Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Oncology, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China. [2]School of Public Health, Kunming Medical University, Kunming, 650000, China. [3]Department of Radiotherapy, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510655, China. [4]Department of Nursing, Dazhou Vocational and Technical College, Dazhou, 635000, Sichuan, China. [5]Department of Clinical Laboratory,The First Affiliated Hospital of Kunming Medical University,Kunming,650118,China. xiongqiuxia1@kmmu.edu.cn. [6]Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, China. xiongqiuxia1@kmmu.edu.cn. [7]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China. xiongqiuxia1@kmmu.edu.cn.
出处:
ISSN:

关键词: Postoperative CEA Recurrence risk Stage II colon cancer Adjuvant chemotherapy

摘要:
Most clinical doctors rely on high-risk factors recommended by guidelines to decide whether to undergo adjuvant chemotherapy for stage II colon cancer. However, these high-risk factors do not include postoperative carcinoembryonic antigen (CEA). This study aims to explore the elevation of postoperative CEA as a risk factor, in addition to other high-risk factors, to guide adjuvant chemotherapy for patients with stage II colon cancer. A retrospective analysis was conducted on stage II colon cancer patients who underwent curative surgery at Yunnan Cancer Hospital and The Sixth Affiliated Hospital of Sun Yat-Sen University from April 2008 to January 2019. Patients were classified into three groups based on high-risk factors recommended by guidelines and postoperative CEA levels: low-risk with normal postoperative CEA, low-risk with elevated postoperative CEA and high-risk. COX regression analysis was used to identify independent prognostic factors affecting patients' recurrence free survival (RFS). The Kaplan-Meier method was used to create the patients' RFS curve. The restricted cubic spline (RCS) curve was used to assess the correlation between postoperative CEA and RFS on a continuous scale. Among 761 patients, there were 444 males (62.01%), with a median [IQR] age of 58.0 (18.0-88.0) years. A group of 425 high-risk patients had a 3-year RFS of 82.2% (95% CI 78.5-86.1%), while a group of 291 low-risk patients had a 3-year RFS of 89.7% (95% CI 86.1-93.5%). There was a statistically significant difference between the two groups (HR 1.83; 95% CI 1.22-2.74; P = 0.0067). Among them, the 3-year RFS of 261 low-risk patients with normal postoperative CEA was 93.6% (95% CI 90.5-96.8%), while the 3-year RFS of 30 low-risk patients with elevated postoperative CEA was 57.3% (95% CI 41.8-71.4%). There was a significant difference compared to the 3-year RFS of 425 high-risk patients (overall log-rank P < 0.0001). The multivariate analysis adjusted by the COX proportional hazards model showed that low-risk patients with elevated postoperative CEA patients (HR 14.95, 95% CI 4.51-49.63, P < 0.0001) was independently associated with a 3-year RFS. The restricted cubic spline model showed that in stage II colon cancer patients with tumor diameter > 1.955 ng/mL, the risk of postoperative recurrence increased with increasing postoperative CEA levels. Patients with elevated postoperative CEA levels have a significantly increased risk of recurrence. They should be included as high-risk factors to guide adjuvant chemotherapy for stage II colon cancer.© 2024. The Author(s).

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
最新[2023]版:
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Department of Oncology, Dazhou Central Hospital, Dazhou, 635000, Sichuan, China.
共同第一作者:
通讯作者:
通讯机构: [5]Department of Clinical Laboratory,The First Affiliated Hospital of Kunming Medical University,Kunming,650118,China. xiongqiuxia1@kmmu.edu.cn. [6]Yunnan Key Laboratory of Laboratory Medicine, Kunming, 650032, China. xiongqiuxia1@kmmu.edu.cn. [7]Yunnan Province Clinical Research Center for Laboratory Medicine, Kunming, 650032, China. xiongqiuxia1@kmmu.edu.cn.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53661 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)